Back

Epigenome-wide association study, meta-analysis and risk profiling of whole blood in Parkinson's disease

Lie, I. H.; Tan, M. M. X.; Andersen, M. S.; Toft, M.; Pihlstrom, L.

2024-05-28 neurology
10.1101/2024.05.28.24308034 medRxiv
Show abstract

An increasing body of evidence indicates altered DNA methylation in Parkinsons disease (PD), yet the reproducibility and utility of such methylation changes are largely unexplored. We conducted an epigenome-wide association study (EWAS) in whole blood, including 280 PD and 279 control participants from Oslo, Norway. In meta-analysis with data from the Parkinsons Progression Markers Initiative (PPMI) and a previously published whole blood PD EWAS (total N=3068) we confirm SLC7A11 hypermethylation and nominate a novel suggestive differentially methylated CpG near LPIN1. A joint multiscore risk profiling model incorporating polygenic risk and methylation-based estimates of epigenetic PD risk, smoking and leukocyte proportions differentiated patients from control participants with an area under the receiver-operator curve or 0.82 in the Oslo cohort and 0.65 in PPMI. Our results highlight the power of DNA methylation profiling to capture multiple aspects of disease risk, indicating a biomarker potential for precision medicine in neurodegenerative disorders.

Matching journals

The top 9 journals account for 50% of the predicted probability mass.

50% of probability mass above

"Similar papers" are the closest papers from that journal in the model's embedding space. They show what the match is built on, but the ranking comes mostly from a classifier over the whole training set, not from these examples alone.